The Heart in Systemic Autoimmune Diseases

The Heart in Systemic Autoimmune Diseases

2nd Edition - February 11, 2017
This is the Latest Edition
  • Editors: Fabiola Atzeni, Andrea Dorea, Mike Nurmohamed, Paolo Pauletto
  • eBook ISBN: 9780444636690
  • Hardcover ISBN: 9780128039977

Purchase options

Purchase options
DRM-free (EPub, PDF, Mobi)
Delivery may take up to 10 days
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

The Heart in Systemic Autoimmune Diseases, Second Edition, provides an overview on our current understanding of major complications relating to the heart and autoimmune diseases. It includes the latest information on the new pathogenetic mechanisms involved, along with clinical manifestations of these important comortbidities. Mortality in autoimmune diseases, in particular, rheumatoid arthritis and SLE, has increased when compared with the general population. This excess mortality is largely due to cardiovascular diseases (CVDs)-particularly those of atherosclerotic origin, such as ischemic heart disease-and is gaining recognition in all branches of medicine, from cardiology, to internal medicine, and from rheumatologists to orthopedics.

Key Features

  • Presents an impressive body of well ordered information on the topic of cardiovascular diseases and their relationship to autoimmune illness
  • Highlights key references
  • Summarizes the experience of a selected panel of distinguished physician-scientists who are actively involved in the field of cardiovascular disease and systemic autoimmunity

Table of Contents

  • Chapter 1. Cellular Immunity: A Role for Cytokines

    • 1. Introduction
    • 2. Autoimmunity in Myocarditis
    • 3. Pathogenesis: The Role of Cells and Cytokines

    Chapter 2. Organ-Specific Autoimmunity Involvement in Cardiovascular Disease

    • 1. Introduction
    • 2. Post-Myocardial Infarction (Dressler) Syndrome
    • 3. Post-Pericardiotomy Syndrome and Idiopathic Recurrent Acute Pericarditis
    • 4. Rheumatic Carditis
    • 5. Dilated Cardiomyopathy and Myocarditis
    • 6. Idiopathic Tachy and Bradyarrhythmias
    • 7. Systemic Arterial Hypertension

    Chapter 3. Neonatal Lupus Syndromes: Pathogenesis and Clinical Features

    • 1. Introduction
    • 2. Epidemiology and Definition of Congenital Complete AVB
    • 3. Etiology/Pathogenesis
    • 4. Risk of Delivering a Child With Complete CHB
    • 5. Clinical Manifestations
    • 6. Treatment
    • 7. Obstetric Management of Pregnancies at Risk of Developing CCHB
    • 8. Prognosis
    • 9. Other Pregnancy Outcomes in Women With Anti-Ro/SSA Antibodies
    • 10. Anti-Ro/SSA Negative CHB

    Chapter 4. Subclinical Cardiovascular Damage in Systemic Rheumatic Diseases

    • 1. Introduction
    • 2. Epidemiology and Role of Traditional Risk Factors
    • 3. Subclinical Atherosclerosis
    • 4. Cardiovascular Effects of Pharmacological Treatments

    Chapter 5. Atherosclerosis and Autoimmunity

    • 1. Introduction
    • 2. Prevalence and Epidemiology
    • 3. Pathogenesis
    • 4. Clinical Manifestations
    • 5. Diagnostic Investigations
    • 6. Treatment

    Chapter 6. Inflammasomes and Inflammatory Cytokines in Early Atherosclerosis

    • 1. Introduction
    • 2. Lipid Dysregulation in Autoimmunity
    • 3. Innate Immunity and Inflammatory Signaling Mechanisms
    • 4. Inflammasomes and IL-1β in Atherogenesis
    • 5. β2-Glycoprotein I in Atherogenic Innate Immunity
    • 6. Summary and Conclusions

    Chapter 7. Treatment of Lipid Metabolism Disturbances in Autoimmune Diseases

    • 1. Introduction
    • 2. Lipid Metabolism Disturbances Relevant for Atherosclerosis and Cardiovascular Risk in Autoimmune Diseases
    • 3. Serum Lipid Level Control in Autoimmune Diseases
    • 4. Lipoprotein Function Modulation in Autoimmune Diseases

    Chapter 8. Cardiac Imaging Techniques in Systemic Autoimmune Diseases

    • 1. Introduction
    • 2. Transthoracic Echocardiography
    • 3. Transesophageal Echocardiography
    • 4. Stress Echocardiography
    • 5. Tissue Doppler Imaging
    • 6. Speckle Tracking Echocardiography
    • 7. Myocardial Contrast Echocardiography
    • 8. Usefulness of Biomarkers of Endothelial Dysfunction
    • 9. Carotid Ultrasonography
    • 10. Conclusion

    Chapter 9. New Cardiac Imaging Tools and Invasive Techniques in Systemic Autoimmune Diseases (Part II)

    • 1. Introduction
    • 2. Cardiac Magnetic Resonance Imaging
    • 3. Computed Tomography
    • 4. Right Heart Catheterization
    • 5. Endomyocardial Biopsy
    • 6. Conclusion

    Chapter 10. Cardiac Diseases in Rheumatoid Arthritis

    • 1. Introduction
    • 2. Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis
    • 3. Nonatherosclerotic Cardiovascular Disease
    • 4. Conclusion

    Chapter 11. Cardiac Involvement in Systemic Lupus Erythematosus

    • 1. Introduction
    • 2. Pericardial Involvement
    • 3. Myocardial Involvement
    • 4. Valvular Involvement
    • 5. Coronary Artery Involvement
    • 6. Conduction Tissue Involvement
    • 7. Conclusions

    Chapter 12. Cardiac Involvement in the Antiphospholipid Syndrome

    • 1. Introduction
    • 2. Epidemiology
    • 3. Pathophysiology
    • 4. Clinical Manifestations
    • 5. Diagnostic Procedures
    • 6. Differential Diagnosis
    • 7. Treatment
    • 8. Final Remarks

    Chapter 13. Cardiac Involvement in Scleroderma

    • 1. Introduction
    • 2. Evidence for and Prognostic Impact of Clinical Cardiac Involvement
    • 3. Prevalence of Subclinical Cardiac Involvement
    • 4. Ischemic Heart Disease
    • 5. Myocarditis
    • 6. Hypertension
    • 7. Arrhythmias
    • 8. The Future

    Chapter 14. Cardiac Involvement in Systemic Vasculitis

    • 1. Introduction
    • 2. Pathogenesis of Vasculitides
    • 3. Cardiovascular Clinical Manifestations in Vasculitides
    • 4. Evolution and Prognostic Factors
    • 5. Treatment
    • 6. Conclusions

    Chapter 15. Cardiovascular Involvement in Ankylosing Spondylitis

    • 1. Introduction
    • 2. Cardiovascular Mortality in Ankylosing Spondylitis
    • 3. Vascular Morbidity in Ankylosing Spondylitis
    • 4. Cardiovascular Risk Factors in Ankylosing Spondylitis
    • 5. Aortic Disease in Ankylosing Spondylitis
    • 6. Mitral Valve Involvement in Ankylosing Spondylitis
    • 7. Conduction Abnormalities in Ankylosing Spondylitis
    • 8. Myocardium and Pericardium in Ankylosing Spondylitis
    • 9. Subclinical Vascular Involvement in Ankylosing Spondylitis
    • 10. Treatment and Its Implications in Atherosclerosis in Ankylosing Spondylitis
    • 11. Conclusions

    Chapter 16. Cardiovascular Involvement in Psoriatic Arthritis

    • 1. Introduction
    • 2. Epidemiology
    • 3. Etiology/Pathogenesis
    • 4. Clinical Manifestations
    • 5. Diagnostic Investigations
    • 6. Treatment

    Chapter 17. Cardiovascular Involvement in Primary Sjögren's Syndrome

    • 1. Introduction
    • 2. Raynaud Phenomenon
    • 3. Cardiovascular Disease
    • 4. Autonomic Cardiovascular Features
    • 5. Pulmonary Arterial Hypertension
    • 6. Arrhythmias
    • 7. Pericarditis
    • 8. Myocarditis

    Chapter 18. Gout and Heart Disease: A Two-Way Street?

    • 1. Introduction
    • 2. Gout—Overview
    • 3. Cardiovascular Disease
    • 4. Gout and Traditional Cardiovascular Risk Factors
    • 5. Etiology and Pathogenesis
    • 6. Diagnostic Interventions
    • 7. Treatment
    • 8. Future Perspectives
    • 9. Conclusion

    Chapter 19. Heart Involvement in Osteoarthritis

    • 1. Introduction
    • 2. Prerequisites: Pathophysiology of Osteoarthritis
    • 3. Epidemiologic Data: Osteoarthritis and Cardiovascular Diseases, Two Endemic Diseases
    • 4. Association Between Osteoarthritis and Cardiovascular Diseases: Shared Risk Factors
    • 5. Association Between Osteoarthritis and Cardiovascular Diseases: Direct Link Beyond CV Risk Factors
    • 6. Association Between Osteoarthritis and Cardiovascular Diseases: an Epiphenomenon?
    • 7. New Perspectives: The Role of Microbiota
    • 8. Conclusions

    Chapter 20. Cardiac Effects of Antirheumatic Drugs

    • 1. Introduction
    • 2. Atherosclerosis and Metabolic Syndrome
    • 3. Other Heart Diseases
    • 4. Recommendations for Cardiovascular Risk Management in Arthritides
    • 5. Conclusions

Product details

  • No. of pages: 566
  • Language: English
  • Copyright: © Elsevier Science 2017
  • Published: February 11, 2017
  • Imprint: Elsevier Science
  • eBook ISBN: 9780444636690
  • Hardcover ISBN: 9780128039977
  • About the Editors

    Fabiola Atzeni

    Fabiola Atzeni
    Fabiola Atzeni is currently a Specialist in Rheumatology and Ph.D. in Experimental Immunology by the University of Barcelona. Her clinical and research interest lies in immunotherapies in autoimmune diseases with particular focus on the investigation and management of differential response to biological therapies in rheumatoid arthritis (RA) and Spondyloarthritis (SpA), and cardiovascular aspects of the different rheumatic diseases with particular emphasis on arteriosclerosis. Dr. Atzeni has (co)authored over 400 publications in peer-reviewed journals and several book chapters, is a regular reviewer for several international journals Arthritis Research Therapy, Journal of Rheumatology and PlosOne, Lupus, Clinical Experimental. She is involved in several (international/national) meetings focused on cardiovascular and infection aspects in rheumatic disease.

    Affiliations and Expertise

    Specialist in Rheumatology, Experimental Immunology, University of Barcelona, Barcelona, Catalonia, Spain

    Andrea Dorea

    Andrea Dorea

    Professor Doria received his medical degree and qualification in Rheumatology from the University of Padua. He was Council member of Italian College of Rheumatology (CRO) between 1999 and 2005 and a Council member of Italian Society of Rheumatology (SIR) from 2007 to 2010 and from 2013 up to now. He is also a member of American College of Rheumatology (ACR).

    Professor Doria has organised over ten international conferences on autoimmunity and was involved as “expert” in the EUropean League Against Rheumatism (EULAR) Standing Committee for the development of clinical and therapeutic recommendations: (1) EULAR recommendations for the management of systemic lupus erythematosus (SLE)—Assessment of the SLE patient (2008–2009); (2) EULAR recommendations for the management of SLE Part II—Neuropsychiatric disease (2008–2009); (3) Joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis (2012). Professor Doria is a member of the Lupus Academy Steering Committee co-Chaired the 4th Annual Meeting held in Rome 27th February to 1st March 2015. He will also chair the 10th European Lupus Meeting which will be held in Venice (Italy) 5–8 October 2016. Professor Doria is on the Editorial Boards of several rheumatology and immunology journals, including Lupus, Autoimmunity, Clinical and Experimental Rheumatology, Autoimmunity Reviews, Journal of Autoimmunity, Experimental Biology and Medicine, Rheumatology Reports, Journal Autoimmunity Highlights and Reumatismo (the official journal of Italian Society of Rheumatology).

    He has authored over 250 ISI publications on SLE and other connective tissue diseases. These include clinical studies describing new manifestations or subgroup of autoimmune disorders, prognostic risk factors, diagnostic tests and therapeutic interventions as well as immunochemical studies that evaluate autoantibodies, epitopes and complementary epitopes of autoantigens. In addition, he has authored and co-authored three books, over 90 book chapters and conference proceedings, and over 500 abstracts to national and international conferences.

    Professor Doria has a long-standing experience in clinical management of connective tissue disease patients. The Unit in which he works is a 3rd referral rheumatology centre, within Italy, for the diagnosis and management of patients affected with systemic connective diseases. In addition, he has expertise in the management and follow-up of pregnant patients with systemic rheumatic diseases. Professor Doria has also trained over 30 students in Rheumatology.

    Affiliations and Expertise

    Professor of Rheumatology and Head of the Unit of Connective Tissue Disease and Rare Rheumatic Diseases, Division of Rheumatology, Department of Medicine, University of Padua, Italy

    Mike Nurmohamed

    Mike Nurmohamed
    Michael Nurmohamed is Rheumatologist and professor of Rheumatology at the VU University Medical Center, Amsterdam, The Netherlands. His chair has a focus on cardiovascular comorbidities in rheumatic diseases/vascular rheumatology. Furthermore, he is the Head of Rheumatology Research Dept. of Reade where he also works as Rheumatologist and Clinical Research Scientist since 2000. Dr. Nurmohamed has (co)authored over 200 publications in peer-reviewed journals and several book chapters, is a regular reviewer for several international journals and an editorial board member of Annals of Rheumatic Diseases , Arthritis Research Therapy, Journal of Rheumatology and PlosOne. He serves on several (international) boards of cardiovascular scientific societies.

    Affiliations and Expertise

    Professor of Rheumatology at the VU University Medical Center, Amsterdam, Netherlands

    Paolo Pauletto

    Paolo Pauletto

    Affiliations and Expertise

    Professor of Internal Medicine, University of Padova Medical School, Italy